|
US5998633A
(en)
*
|
1996-07-29 |
1999-12-07 |
Warner-Lambert Company |
Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid
|
|
KR100332703B1
(ko)
*
|
1998-07-24 |
2002-08-27 |
삼성정밀화학 주식회사 |
광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
|
|
CN1316008A
(zh)
|
1998-07-24 |
2001-10-03 |
三星精密化学株式会社 |
制备α－(1,4)－连接的寡糖的方法
|
|
US6713290B2
(en)
|
1998-07-24 |
2004-03-30 |
Samsung Fine Chemicals Co., Ltd. |
Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
|
|
US6235930B1
(en)
*
|
1999-03-31 |
2001-05-22 |
Board Of Trustees Operating Michigan State University |
Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
|
|
HU227840B1
(en)
*
|
1999-05-06 |
2012-05-02 |
Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag |
Intermediates of atorvastatin synthesis and process for producing them
|
|
DE60026737T2
(de)
*
|
1999-12-17 |
2006-09-21 |
Pfizer Science And Technology Ireland Ltd., Dun Laoghaire |
Verfahren zur herstellung von kristallin atorvastin kalcium
|
|
WO2001044180A1
(en)
|
1999-12-17 |
2001-06-21 |
Warner Lambert Research And Development Ireland Limited |
A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
|
|
JP4598917B2
(ja)
*
|
2000-04-28 |
2010-12-15 |
ダイセル化学工業株式会社 |
ラクトンの製造方法
|
|
KR100645665B1
(ko)
|
2000-07-27 |
2006-11-13 |
에스케이 주식회사 |
(ｓ)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
|
|
EP1734034A3
(en)
|
2001-01-09 |
2007-01-03 |
Warner-Lambert Company LLC |
Carboxylic acid salts of beta-alanine esters or -amides
|
|
US6476235B2
(en)
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
|
AP1571A
(en)
|
2001-06-29 |
2006-02-10 |
Warner Lambert Co |
Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
|
|
CA2451159A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
|
|
KR100598079B1
(ko)
*
|
2002-02-25 |
2006-07-07 |
바이오콘 리미티드 |
신규의 보로네이트 에스테르
|
|
GB0211716D0
(en)
|
2002-05-22 |
2002-07-03 |
Phoenix Chemicals Ltd |
Process
|
|
JP2005539018A
(ja)
*
|
2002-08-06 |
2005-12-22 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
５−（４−フルオロフェニル）−１−［２−（（２ｒ，４ｒ）−４−ヒドロキシ−６−オキソ−テトラヒドロ−ピラン−２−イル）エチル］−２−イソプロピル−４−フェニル−１ｈ−ピロール−３−カルボン酸フェニルアミドの製造方法
|
|
US20060052617A1
(en)
*
|
2002-09-18 |
2006-03-09 |
Sk Corporation |
Continuous process for the production of optically pure (s)-beta-hydroxy-y-butyrolactone
|
|
US7414119B2
(en)
*
|
2002-09-20 |
2008-08-19 |
Verenium Corporation |
Aldolases, nucleic acids encoding them and methods for making and using them
|
|
US6713639B1
(en)
|
2002-10-28 |
2004-03-30 |
Council Of Scientific And Industrial Research |
Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
|
|
RU2337905C2
(ru)
*
|
2003-04-14 |
2008-11-10 |
Уорнер-Ламберт Компани Ллс |
Способ получения фениламида 5-(4-фторфенил)-1-[2-((2r,4r)-4-гидрокси-6-оксотетрагидропиран-2-ил)этил]-2-изопропил-4-фенил-1h-пиррол-3-карбоновой кислоты
|
|
ES2323366T3
(es)
*
|
2003-04-22 |
2009-07-14 |
Biocon Limited |
Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres.
|
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
CN1852894A
(zh)
*
|
2003-09-17 |
2006-10-25 |
沃尼尔·朗伯有限责任公司 |
[R－(R*, R*)]－2－(4－氟苯基) －β,δ－二羟基－5－(1－甲基乙基) －3－苯基－4－[(苯基氨基)羰基] －1 H－吡咯－1－庚酸的结晶形式
|
|
WO2005068642A2
(en)
|
2003-10-01 |
2005-07-28 |
Board Of Trustees Operating Michigan State University |
Bacterial synthesis of 1,2,4-butanetriol enantiomers
|
|
KR100829268B1
(ko)
*
|
2004-04-16 |
2008-05-13 |
화이자 프로덕츠 인코포레이티드 |
비정질 아토바스타틴 칼슘의 제조 방법
|
|
BRPI0510713A
(pt)
|
2004-05-05 |
2007-11-20 |
Pfizer Prod Inc |
formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
|
|
MX2007000765A
(es)
|
2004-07-20 |
2007-03-28 |
Warner Lambert Co |
Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
|
|
CN101048141A
(zh)
|
2004-10-28 |
2007-10-03 |
沃尼尔·朗伯有限责任公司 |
形成非晶形的阿托伐他汀的方法
|
|
JP2008521878A
(ja)
*
|
2004-12-02 |
2008-06-26 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
非晶質アトルバスタチンの医薬組成物及びその製造のための方法
|
|
DE602006013815D1
(de)
*
|
2005-05-31 |
2010-06-02 |
Kowa Co |
Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung
|
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
|
WO2007057755A1
(en)
|
2005-11-21 |
2007-05-24 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
|
|
US20110165641A1
(en)
*
|
2006-03-31 |
2011-07-07 |
The Board Of Trustees Of Michigan State University |
Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
|
|
EP2054518A2
(en)
*
|
2006-07-19 |
2009-05-06 |
Board of Trustees of Michigan State University |
Microbial synthesis of d-1,2,4-butanetriol
|
|
KR100850558B1
(ko)
|
2008-01-02 |
2008-08-06 |
조동옥 |
아토르바스타틴의 효율적인 제조방법
|
|
JP2009256316A
(ja)
|
2008-03-28 |
2009-11-05 |
Daicel Chem Ind Ltd |
β−ヒドロキシ−γ−ブチロラクトンの製造方法
|
|
CN101337906B
(zh)
*
|
2008-08-15 |
2012-06-27 |
河南豫辰精细化工有限公司 |
一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
|
|
EP2327682A1
(en)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2373609B1
(en)
|
2008-12-19 |
2013-10-16 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
US20140335179A1
(en)
|
2011-07-01 |
2014-11-13 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Micronized crystals of atorvastatin hemicalcium
|
|
CN106397241A
(zh)
*
|
2016-08-23 |
2017-02-15 |
杨锋 |
一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
|
|
CN106588689A
(zh)
*
|
2016-12-15 |
2017-04-26 |
河南豫辰药业股份有限公司 |
一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
|
|
CN112939901B
(zh)
*
|
2021-02-09 |
2023-05-09 |
中国科学院福建物质结构研究所 |
一种α-羟基-γ-丁内酯的制备方法
|
|
CN114195670B
(zh)
*
|
2021-12-31 |
2024-03-15 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀母核m4的精制方法
|
|
CN117447350A
(zh)
*
|
2023-10-26 |
2024-01-26 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀m4有机废物综合再利用方法
|